John Kim
@jskim8223.bsky.social
π€ 130
π₯ 93
π 11
Pulmonologist with research interests in ILD at the University of Virginia
Recently sent this piece from
@insight.jci.org
on guide to K award applications for physician-scientists to a PCCM fellow:
insight.jci.org/articles/vie...
@atscommunity.bsky.social
@ats-clinicalprobs.bsky.social
loading . . .
JCI Insight - An insiderβs guide to understanding and obtaining an NIH K career development award
https://insight.jci.org/articles/view/191904
about 2 months ago
0
1
0
reposted by
John Kim
KaminskiMed
about 2 months ago
Finally in Print! The Official ATS Research Statement on Racial, Ethnic, Sex & Gender Equity for Inclusive Interstitial Lung Disease Research. ππΌ Drs Assayag, Adegonsoye, Cottin, Mageto &
@atsblueeditor.bsky.social
&
@atscommunity.bsky.social
#CurePF4All
www.atsjournals.org/doi/10.1164/...
0
8
4
reposted by
John Kim
Kerri Johannson MD MPH
3 months ago
Okay
#MedSky
#AcademicSky
π What is the optimal number of reviewers for a run-of-the-mill manuscript @ reg journal (i.e. not Science/NEJM) Some journals invite 4-5 as default π€― I think 2 is sufficient, max 3 if controversy More reviewers β‘οΈ less AE provides input And SO many hours of free labour πͺ
2
10
3
Thrilled our paper made it to the
@atsblueeditor.bsky.social
ILD issue this month. Look forward to building on this work and welcome collaboration with anyone interested in subclinical pulmonary fibrosis. I think a future research area is mapping the blood-lung proteome in this context.
add a skeleton here at some point
4 months ago
0
0
0
reposted by
John Kim
ATS Blue Journal
4 months ago
The Blue Journal thanks Riley Hannan, PhD, for his contribution to the October issue Associations of High Attenuation Area-Related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities
@jskim8223.bsky.social
www.atsjournals.org/doi/full/10....
0
1
1
Our paper is online
@atsblueeditor.bsky.social
identifying plasma protein markers with HAA and correlating to new-onset fibrotic/subpleural ILA. Big thanks to our collaborators in
#MESA
&
#SPIROMICS
!
www.atsjournals.org/doi/abs/10.1...
loading . . .
Associations of High Attenuation Area-related Proteomic Biomarkers with Fibrotic or Subpleural Interstitial Lung Abnormalities | American Journal of Respiratory and Critical Care Medicine | Articles i...
https://www.atsjournals.org/doi/abs/10.1164/rccm.202503-0610OC
5 months ago
0
2
0
reposted by
John Kim
ATS Blue Journal
6 months ago
Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement
@atscommunity.bsky.social
#medsky
π Open Access π
tinyurl.com/4vjm9zdw
0
5
4
Current work playlist while writing. Any other music
#PCCM
are putting on in the background for work?
@kaminskimed.bsky.social
@kerrijohannson.bsky.social
@ipfdoc.bsky.social
@drdayjee.bsky.social
@emilyfri.bsky.social
@drpujamehta1.bsky.social
?
open.spotify.com/playlist/37i...
loading . . .
Sinners Official Playlist
Playlist Β· Spotify Β· 74 items Β· 50.9K saves
https://open.spotify.com/playlist/37i9dQZF1DX9cgnKcytSCK?si=upX-J3tnRiaoH-uPe3WMng
9 months ago
4
5
1
reposted by
John Kim
The Lancet Respiratory Medicine
9 months ago
𧬠Rare variants and survival of patients with idiopathic pulmonary fibrosis: analysis of a multicentre, observational cohort study with independent validation π Non-additive effects were seen between qualifying variants and common risk variants in
#IPF
survival π
www.thelancet.com/journals/lan...
1
2
2
reposted by
John Kim
Aitana Alonso
9 months ago
Delighted to share our new study evaluating the association of rare variants in telomere and non-telomere monogenic adult-onset Pulmonary Fibrosis genes and IPF patient survival where we also intersected their effects with
#PRS
of IPF.
add a skeleton here at some point
1
4
4
Had the privilege giving a talk about early ILD detection and sharing some of the research we are doing at
#KATRD
annual meeting in
#Gyeongju
. Thank you for the opportunity and meeting so many wonderful pulmonologists.
10 months ago
0
2
0
Informative piece in
@naturerevdrugdisc.bsky.social
on cross-organ fibrosis and informing drug development.
@ipfdoc.bsky.social
@gilliangoobie.bsky.social
@kerrijohannson.bsky.social
@kaminskimed.bsky.social
@tkulkarni.bsky.social
@drdayjee.bsky.social
www.nature.com/articles/s41...
loading . . .
Fibrosis: cross-organ biology and pathways to development of innovative drugs - Nature Reviews Drug Discovery
Fibrosis is a key characteristic of a range of chronic diseases that has been challenging to target with drugs. This Review highlights core pathways active in fibrotic conditions across organs, as wel...
https://www.nature.com/articles/s41573-025-01158-9
10 months ago
0
13
4
reposted by
John Kim
Nick Banovich
12 months ago
Excited to post my first
#skySplain
about our recent work published yesterday in Nature Genetics!
www.nature.com/articles/s41...
. One of the first authors of this study - Annika Vannan β actually wrote this breakdown, but she's not yet over here on bluesky and asked me to post!
loading . . .
Spatial transcriptomics identifies molecular niche dysregulation associated with distal lung remodeling in pulmonary fibrosis - Nature Genetics
Xenium spatial transcriptomic profiling of pulmonary fibrosis characterizes cell composition dynamics and histopathological features associated with the disease.
https://www.nature.com/articles/s41588-025-02080-x
3
55
26
reposted by
John Kim
Annals of the ATS
about 1 year ago
Genomic and Serological Rheumatoid Arthritis Biomarkers, MUC5B Promoter Variant, and Interstitial Lung Abnormalities
@atscommunity.bsky.social
#medsky
π
tinyurl.com/mr4cke25
0
6
2
reposted by
John Kim
Kerri Johannson MD MPH
about 1 year ago
π Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease π Just out in
@atsblueeditor.bsky.social
π«
www.atsjournals.org/doi/abs/10.1...
State of the Art: -Epidemiology -Mechanisms of Injury -Implications - clinical & policy -Future directions
1
21
6
reposted by
John Kim
Kerri Johannson MD MPH
about 1 year ago
Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?
@ipfdoc.bsky.social
@kaminskimed.bsky.social
#CurePF
#CureIPF
@ats-clinicalprobs.bsky.social
@tkulkarni.bsky.social
@jskim8223.bsky.social
pmc.ncbi.nlm.nih.gov/articles/pmi...
2
10
6
reposted by
John Kim
ATS Blue Journal
about 1 year ago
The Blue Journal thanks Catherine L. Debban, PhD, for her contribution to the December 15 issue Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan
www.atsjournals.org/doi/full/10....
0
2
1
reposted by
John Kim
Jack Iwashyna
about 1 year ago
last night, Hallie Prescott had her NEJM review on sepsis released:
www.nejm.org/doi/full/10....
Today I had the pleasure of giving some remarks on her installation as the Toews Family Legacy Professor at the University of Michigan
loading . . .
Sepsis and Septic Shock | NEJM
Sepsis is a life-threatening, heterogeneous disorder involving a dysregulated immune response to infection. Research to identify subtypes and targeted therapies for host dysregulation is ongoing.
https://www.nejm.org/doi/full/10.1056/NEJMra2403213
3
62
15
reposted by
John Kim
GΓsli
about 1 year ago
Using Mendelian Randomisation to identify causal associations in
#IPF
a π§΅
1
8
6
reposted by
John Kim
Kerri Johannson MD MPH
about 1 year ago
For the new BlueSky members who have left
#ILDTwitter
Iβve updated this starter-pack to help you find key ILD and ILD-adjacent community members here. Pls comment if Iβve missed you and Iβll add you π«π
#CurePF
#CureIPF
#ILD
go.bsky.app/8u4KcNo
add a skeleton here at some point
5
13
8
you reached the end!!
feeds!
log in